Biogen, Inc.
(NASDAQ : BIIB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.07%200.801.3%$462.93m
BIIBBiogen Inc.
0.09%223.211.3%$371.70m
GILDGilead Sciences, Inc.
1.15%63.990.9%$363.00m
CELGCelgene Corporation
0.76%100.571.3%$359.89m
ILMNIllumina, Inc.
1.48%302.583.5%$282.38m
REGNRegeneron Pharmaceuticals, Inc.
0.81%300.772.6%$210.74m
EXASExact Sciences Corporation
2.19%92.5024.1%$193.04m
VRTXVertex Pharmaceuticals Incorporated
1.29%172.411.9%$181.51m
ALXNAlexion Pharmaceuticals, Inc.
0.92%99.252.0%$176.54m
AAgilent Technologies, Inc.
1.77%75.311.6%$166.98m
SRPTSarepta Therapeutics, Inc.
0.39%83.4814.6%$138.14m
ALDRAlder Biopharmaceuticals, Inc.
-0.05%18.8710.2%$125.33m
BMRNBioMarin Pharmaceutical Inc.
1.29%67.364.3%$96.05m
ACADACADIA Pharmaceuticals Inc.
0.10%40.5213.4%$95.97m
INCYIncyte Corporation
0.46%76.122.5%$87.99m

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.